M. Lapointe et al., Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation, CLIN TRANSP, 13(6), 1999, pp. 526-530
Nephrotoxicity remains one of the most common side-effects of cyclosporine
in the setting of transplantation, Acute reversible decreases in glomerular
filtration rate and chronic irreversible renal damage are the most common
manifestations, but hemolytic uremic syndrome and thrombotic thrombocytopen
ic purpura have been reported. Prognosis of cyclosporine-associated de novo
hemolytic uremic syndrome (CyA-HUS) is poor, with nearly half of affected
patients losing function in the transplanted kidney. Therapeutic options ar
e limited, but good outcomes have been reported by switching patients from
cyclosporine to tacrolimus. We report an unusual presentation of CyA-HUS as
sociated with hemorrhagic colitis following renal transplantation. The pati
ent was successfully managed by switching from cyclosporine to tacrolimus.